506 related articles for article (PubMed ID: 32850376)
1. CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions.
Rodríguez-Lobato LG; Ganzetti M; Fernández de Larrea C; Hudecek M; Einsele H; Danhof S
Front Oncol; 2020; 10():1243. PubMed ID: 32850376
[TBL] [Abstract][Full Text] [Related]
2. European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma.
Bruno B; Wäsch R; Engelhardt M; Gay F; Giaccone L; D'Agostino M; Rodríguez-Lobato LG; Danhof S; Gagelmann N; Kröger N; Popat R; Van de Donk NWCJ; Terpos E; Dimopoulos MA; Sonneveld P; Einsele H; Boccadoro M
Haematologica; 2021 Aug; 106(8):2054-2065. PubMed ID: 33792221
[TBL] [Abstract][Full Text] [Related]
3. [CAR-T cells immunotherapy in multiple myeloma: Present and future].
Ferment B; Arnulf B
Bull Cancer; 2021 Oct; 108(10S):S65-S72. PubMed ID: 34920809
[TBL] [Abstract][Full Text] [Related]
4. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.
Anderson LD
Future Oncol; 2022 Jan; 18(3):277-289. PubMed ID: 34854741
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice.
Parikh RH; Lonial S
CA Cancer J Clin; 2023; 73(3):275-285. PubMed ID: 36627265
[TBL] [Abstract][Full Text] [Related]
6. Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma.
Miller K; Hashmi H; Rajeeve S
Front Oncol; 2024; 14():1398902. PubMed ID: 38800372
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience of CAR T cells for multiple myeloma.
Simmons GL; Satta T; Castaneda Puglianini O
Best Pract Res Clin Haematol; 2021 Sep; 34(3):101306. PubMed ID: 34625232
[TBL] [Abstract][Full Text] [Related]
8. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
[TBL] [Abstract][Full Text] [Related]
9. CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update.
Cohen AD
Am Soc Clin Oncol Educ Book; 2018 May; 38():e6-e15. PubMed ID: 30231373
[TBL] [Abstract][Full Text] [Related]
10. BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma.
Raghunandan S; Pauly M; Blum WG; Qayed M; Dhodapkar MV; Elkhalifa M; Watkins B; Schoettler M; Horwitz E; Parikh S; Chandrakasan S; Leung K; Bryson E; Deeb L; Kaufman JL; Worthington-White D; Alazraki A; Schecter JM; Madduri D; Jackson CC; Zudaire E; Taraseviciute-Morris A; Babich A; Nesheiwat T; Vogel M; Lendvai N; Pacaud L; Williams KM
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37137553
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen.
Timmers M; Roex G; Wang Y; Campillo-Davo D; Van Tendeloo VFI; Chu Y; Berneman ZN; Luo F; Van Acker HH; Anguille S
Front Immunol; 2019; 10():1613. PubMed ID: 31379824
[TBL] [Abstract][Full Text] [Related]
12. Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma.
García-Guerrero E; Sierro-Martínez B; Pérez-Simón JA
Front Immunol; 2020; 11():1128. PubMed ID: 32582204
[TBL] [Abstract][Full Text] [Related]
13. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.
Yang J; Zhou W; Li D; Niu T; Wang W
Cancer Lett; 2023 Jan; 553():215949. PubMed ID: 36216149
[TBL] [Abstract][Full Text] [Related]
14. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
Davis JA; Shockley A; Hashmi H
J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
[TBL] [Abstract][Full Text] [Related]
15. Update on the current and future use of CAR-T to treat multiple myeloma.
Gahvari Z; Brunner M; Schmidt T; Callander NS
Eur J Haematol; 2024 Apr; 112(4):493-503. PubMed ID: 38099401
[TBL] [Abstract][Full Text] [Related]
16. [Clinical development of chimeric antigen receptor T-cell therapy in multiple myeloma].
Goto H
Rinsho Ketsueki; 2022; 63(6):580-588. PubMed ID: 35831191
[TBL] [Abstract][Full Text] [Related]
17. The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma.
Oriol A; Abril L; Torrent A; Ibarra G; Ribera JM
Ther Adv Hematol; 2021; 12():20406207211019622. PubMed ID: 34104374
[TBL] [Abstract][Full Text] [Related]
18. Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma.
Zhang Q; Zu C; Jing R; Feng Y; Zhang Y; Zhang M; Lv Y; Cui J; Zhou L; Meng Y; Wang L; Cen Z; Chang AH; Hu Y; Huang H
Front Immunol; 2023; 14():1125357. PubMed ID: 37215107
[TBL] [Abstract][Full Text] [Related]
19. Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma.
Chekol Abebe E; Yibeltal Shiferaw M; Tadele Admasu F; Asmamaw Dejenie T
Front Immunol; 2022; 13():991092. PubMed ID: 36119032
[TBL] [Abstract][Full Text] [Related]
20. Idecabtagene vicleucel for relapsed/refractory multiple myeloma: a review of recent advances.
Tu W; Xiao Y; Wang Y; Luo R; Chen ZS
Drugs Today (Barc); 2022 Mar; 58(3):117-132. PubMed ID: 35274631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]